Inluriyo for ESR1-mutated HR-positive HER2-negative advanced breast cancer
Quick answer: Inluriyo is used for ESR1-mutated HR-positive HER2-negative advanced breast cancer as part of a selective estrogen receptor degrader (serd) treatment regimen. Elacestrant binds and degrades the estrogen receptor, blocking estrogen-driven tumor growth The specific dosing for ESR1-mutated HR-positive HER2-negative advanced breast cancer is determined by your prescriber based on individual factors.
Why is Inluriyo used for ESR1-mutated HR-positive HER2-negative advanced breast cancer?
Inluriyo belongs to the Selective estrogen receptor degrader (SERD) class. Elacestrant binds and degrades the estrogen receptor, blocking estrogen-driven tumor growth This action makes it useful for treating or managing ESR1-mutated HR-positive HER2-negative advanced breast cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Inluriyo is the right choice for a specific patient depends on the type and severity of ESR1-mutated HR-positive HER2-negative advanced breast cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for ESR1-mutated HR-positive HER2-negative advanced breast cancer
Common adult dosing range: 345 mg orally once daily. The actual dose for ESR1-mutated HR-positive HER2-negative advanced breast cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Inluriyo medicine page.
What to expect
Inluriyo treatment for ESR1-mutated HR-positive HER2-negative advanced breast cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on ESR1-mutated HR-positive HER2-negative advanced breast cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Inluriyo is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Selective estrogen receptor degrader (SERD) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Inluriyo
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Inluriyo full prescribing information · All Selective estrogen receptor degrader (SERD) alternatives
Frequently asked questions
How effective is Inluriyo for ESR1-mutated HR-positive HER2-negative advanced breast cancer?
Effectiveness varies by individual response, dose, and severity. Inluriyo is one of several treatment options for ESR1-mutated HR-positive HER2-negative advanced breast cancer, supported by clinical evidence within the selective estrogen receptor degrader (serd) class. Discuss expected response with your prescriber.
How long do I need to take Inluriyo for ESR1-mutated HR-positive HER2-negative advanced breast cancer?
Treatment duration depends on the nature of ESR1-mutated HR-positive HER2-negative advanced breast cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Inluriyo when used for ESR1-mutated HR-positive HER2-negative advanced breast cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Inluriyo for ESR1-mutated HR-positive HER2-negative advanced breast cancer?
Yes. Multiple medicines and non-drug options exist for ESR1-mutated HR-positive HER2-negative advanced breast cancer. Alternatives within the selective estrogen receptor degrader (serd) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.